Morris KV & Witwer KW.

The evolving paradigm of extracellular vesicles in intercellular signaling and delivery of therapeutic RNAs.

Mol Ther (2022) 30:2393-2394.

Lu Z et al.

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.

J Clin Invest (2022) 132.

Hao N et al.

Acoustofluidic multimodal diagnostic system for Alzheimer”s disease.

Biosens Bioelectron (2022) 196:113730.

Dragomir MP, Knutsen E & Calin GA.

Classical and noncanonical functions of miRNAs in cancers.

Trends Genet (2022) 38:379-394.

Li J et al.

Acoustic tweezer with complex boundary-free trapping and transport channel controlled by shadow waveguides.

Sci Adv (2021) 7:eabi5502.

Ma S et al.

CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.

Cell Rep (2021) 36:109549.

Ma S et al.

Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.

Cell Rep (2021) 34:108726.

Silverman DA et al.

Cancer-associated neurogenesis and nerve-cancer cross-talk.

Cancer Res (2021) 81:1431-1440.

Anfossi S & Calin GA.

Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy.

Cancer Drug Resist (2020) 3:356-370.

Chen B et al.

The long noncoding RNA CCAT2 induces chromosomal instability through BOP1 – AURKB signaling.

Gastroenterology (2020) 159:2146-2162.e33.

Drula R et al.

MicroRNAs from liquid biopsy derived extracellular vesicles: Recent advances in detection and characterization methods.

Cancers (Basel) (2020) 12:2009.

Chen F et al.

Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in Acute Myeloid Leukaemia: Therapeutic implications.

J Cell Mol Med (2020) 24:7378-7392.

Tran AM et al.

A new world of biomarkers and therapeutics for female reproductive system and breast cancers: Circular RNAs.

Front Cell Dev Biol (2020) 8:50.

Pichler M et al.

Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer.

Gut (2020) 69:1818-1831.

Oliveira GP Jr et al.

Detection of extracellular vesicle RNA using molecular beacons.

iScience (2020) 23:100782.

El-Arabey AA et al.

GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.

Cell Signal (2020) 68:109539.

Parashar D et al.

miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer.

Cell Rep (2019) 29:4389-4406.e10.

De Los Santos MC, Dragomir MP & Calin GA.

The role of exosomal long non-coding RNAs in cancer drug resistance.

Cancer Drug Resist (2019) 2:1178-1192.

Fabbri M et al.

Decrypting noncoding RNA interactions, structures, and functional networks.

Genome Res (2019) 29:1377-1388.

Bach DH, Zhang W & Sood AK.

Chromosomal instability in tumor initiation and development.

Cancer Res (2019) 79:3995-4002.

Bayraktar R, Bertilaccio MTS & Calin GA.

The interaction between two worlds: microRNAs and Toll-Like Receptors.

Front Immunol (2019) 10:1053.

Ma S et al.

GnRH-R-targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition.

Mol Cancer Ther (2019) 18:969-979.

Gonzalez-Villasana V et al.

Presence of circulating miR-145, miR-155, and miR-382 in exosomes isolated from serum of breast cancer patients and healthy donors.

Dis Markers (2019) 2019:6852917.

Bach DH, Lee SK & Sood AK.

Circular RNAs in Cancer.

Mol Ther Nucleic Acids (2019) 16:118-129.

Rodriguez-Aguayo C et al.

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

EBioMedicine (2019) 40:290-304.

Gulei D et al.

CRISPR-based RNA editing: Diagnostic applications and therapeutic options.

Expert Rev Mol Diagn (2019) 19:83-88.

LaFargue CJ et al.

Exploring and comparing adverse events between PARP inhibitors.

Lancet Oncol (2019) 20:e15-e28.

Cortez MA et al.

Role of miRNAs in immune responses and immunotherapy in cancer.

Genes Chromosomes Cancer (2019) 58:244-253.

Villar-Prados A et al.

Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4.

Mol Cancer Ther (2019) 18:421-436.

Van Roosbroeck K et al.

The involvement of microRNA in the pathogenesis of Richter syndrome.

Haematologica (2019) 104:1004-1015.

Hisamatsu T et al.

PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer.

Mol Cancer Ther (2019) 18:162-172.

Shen P et al.

Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling.

Mol Oncol (2018) 12:1856-1870.

Dragomir M, Chen B & Calin GA.

Exosomal lncRNAs as new players in cell-to-cell communication.

Transl Cancer Res (2018) 7:S243-S252.

Silva AM et al.

Profiling the circulating miRnome reveals a temporal regulation of the bone injury response.

Theranostics (2018) 8:3902-3917.

Gharpure KM et al.

FABP4 as a key determinant of metastatic potential of ovarian cancer.

Nat Commun (2018) 9:2923.

Zhang Q et al.

Mutant KRAS exosomes alter the metabolic state of recipient colonic epithelial cells.

Cell Mol Gastroenterol Hepatol (2018) 5:627-629.e6.

Dragomir M & Calin GA.

Circular RNAs in cancer – Lessons learned from microRNAs.

Front Oncol (2018) 8:179.

Lyons YA et al.

Immune cell profiling in cancer: Molecular approaches to cell-specific identification.

NPJ Precis Oncol (2017) 1:26.

Yeung TL et al.

Systematic identification of druggable epithelial-stromal crosstalk signaling networks in ovarian cancer.

J Natl Cancer Inst (2019) 111:272-282.

Haemmerle M et al.

The platelet lifeline to cancer: Challenges and opportunities.

Cancer Cell (2018) 33:965-983.

Shah MY et al.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Genome Res (2018) 28:432-447.

Filant J et al.

Isolation of extracellular RNA from serum/plasma.

Methods Mol Biol (2018) 1740:43-57.

Velazquez-Torres G et al.

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.

Nat Commun (2018) 9:461.

McKenzie JA et al.

The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy.

J Natl Cancer Inst (2018) 110:777-786.

Kanlikilicer P et al.

Therapeutic targeting of AXL receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer models.

Mol Ther Nucleic Acids (2017) 9:251-262.

Soni A et al.

Study protocol for Smartphone Monitoring for Atrial fibrillation in Real-Time in India (SMART-India): a community-based screening and referral programme.

BMJ Open (2017) 7:e017668.

Noh K et al.

Differential effects of EGFL6 on tumor versus wound angiogenesis.

Cell Rep (2017) 21:2785-2795.

Vannini I et al.

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Nat Commun (2017) 8:1801.

Lu Y et al.

MYC targeted long noncoding RNA DANCR promotes cancer in part by reducing p21 levels.

Cancer Res (2018) 78:64-74.

Ren A, Micura R & Patel DJ.

Structure-based mechanistic insights into catalysis by small self-cleaving ribozymes.

Curr Opin Chem Biol (2017) 41:71-83.

Amorim MG et al.

A total transcriptome profiling method for plasma-derived extracellular vesicles: Applications for liquid biopsies.

Sci Rep (2017) 7:14395.

Mitamura T et al.

Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).

Oncogene (2018) 37:722-731.

Willinger CM et al.

MicroRNA signature of cigarette smoking and evidence for a putative causal role of microRNAs in smoking-related inflammation and target organ damage.

Circ Cardiovasc Genet (2017) 10:5.

Bayraktar R, Van Roosbroeck K & Calin GA.

Cell-to-cell communication: microRNAs as hormones.

Mol Oncol (2017) 11:1673-1686.

Shen P et al.

To Wnt or lose: The missing non-coding linc in colorectal cancer.

Int J Mol Sci (2017) 18:9.

Rodriguez-Aguayo C et al.

Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.

Cell Discov (2017) 3:17029.

Figueroa J et al.

Exosomes from glioma-associated mesenchymal stem cells increase the tumorigenicity of glioma stem-like cells via transfer of miR-1587.

Cancer Res (2017) 77:5808-5819.

Dalton HJ et al.

Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression.

Clin Cancer Res (2017) 23:7034-7046.

Wu AY & Lai CP.

Tracking extracellular vesicles delivery and RNA translation using multiplexed reporters.

Methods Mol Biol (2017) 1660:255-265.

Wu X et al.

The many faces of long noncoding RNAs in cancer.

Antioxid Redox Signal (2018) 29:922-935.

Gogakos T et al.

Characterizing expression and processing of precursor and mature human tRNAs by hydro-tRNAseq and PAR-CLIP.

Cell Rep (2017) 20:1463-1475.

Fleming ND et al.

Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.

Gynecol Oncol (2017) 147:41-46.

Sardana M et al.

Clinical and echocardiographic correlates of Left Atrial Function Index: the Framingham offspring study.

J Am Soc Echocardiogr (2017) 30:904-912.e2.

Denizli M et al.

Chitosan nanoparticles for miRNA delivery.

Methods Mol Biol (2017) 1632:219-230.

Fabris L & Calin GA.

Understanding the genomic ultraconservations: T-UCRs and cancer.

Int Rev Cell Mol Biol (2017) 333:159-172.

Saugstad JA et al.

Analysis of extracellular RNA in cerebrospinal fluid.

J Extracell Vesicles (2017) 6:1317577.

Sarkar S et al.

PRKCI promotes immune suppression in ovarian cancer.

Genes Dev (2017) 31:1109-1121.

Silva AM et al.

Dendritic cell-derived extracellular vesicles mediate mesenchymal stem/stromal cell recruitment.

Sci Rep (2017) 7:1667.

Bruno S et al.

Renal regenerative potential of different extracellular vesicle populations derived from bone marrow mesenchymal stromal cells.

Tissue Eng Part A (2017) 23:1262-1273.

Fuentes-Mattei E et al.

Plasma viral miRNAs indicate a high prevalence of occult viral infections.

EBioMedicine (2017) 20:182-192.

Klingenberg M et al.

Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.

J Hepatol (2017) 67:603-618.

Rashed MH et al.

Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.

Oncotarget (2017) 8:20145-20164.

Rabinowicz N et al.

Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.

Oncotarget (2017) 8:27380-27392.

Wagner MJ et al.

Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA).

Mol Cancer Ther (2017) 16:1114-1123.

Gladek I et al.

HIF1A gene polymorphisms and human diseases: Graphical review of 97 association studies.

Genes Chromosomes Cancer (2017) 56:439-452.

Maas SL, Breakefield XO & Weaver AM.

Extracellular vesicles: Unique intercellular delivery vehicles.

Trends Cell Biol (2017) 27:172-188.

Krzeszinski JY et al.

Lipid osteoclastokines regulate breast cancer bone metastasis.

Endocrinology (2017) 158:477-489.

Van Roosbroeck K et al.

Combining anti-miR-155 with chemotherapy for the treatment of lung cancers.

Clin Cancer Res (2017) 23:2891-2904.

Pi F et al.

RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.

Nanomedicine (2017) 13:1183-1193.

Kaczor-Urbanowicz KE et al.

Emerging technologies for salivaomics in cancer detection.

J Cell Mol Med (2017) 21:640-647.

Yang L et al.

Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth.

Cell Metab (2016) 24:685-700.

Previs RA et al.

The rise of genomic profiling in ovarian cancer.

Expert Rev Mol Diagn (2016) 16:1337-1351.

Hatakeyama H et al.

Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers.

Cell Rep (2016) 17:1621-1631.

Ohtsuka M et al.

H19 noncoding RNA, an independent prognostic factor, regulates essential Rb-E2F and CDK8-beta-catenin signaling in colorectal cancer.

EBioMedicine (2016) 13:113-124.

Mangala LS et al.

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

JCI Insight (2016) 1:e87754.

Kanlikilicer P et al.

Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells.

Cancer Res (2016) 76:7194-7207.

Soni A et al.

High burden of unrecognized atrial fibrillation in rural india: An innovative community-based cross-sectional screening program.

JMIR Public Health Surveill (2016) 2:e159.

Giza DE et al.

Cellular and viral microRNAs in sepsis: Mechanisms of action and clinical applications.

Cell Death Differ (2016) 23:1906-1918.

Shah MY et al.

microRNA therapeutics in cancer – an emerging concept.

EBioMedicine (2016) 12:34-42.

Zhou J et al.

A novel compound ARN-3236 inhibits salt-inducible kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.

Clin Cancer Res (2017) 23:1945-1954.

Huang Y et al.

Anti-tumor and anti-angiogenic effects of aspirin-PC in ovarian cancer.

Mol Cancer Ther (2016) 15:2894-2904.

Ciccone M & Calin GA.

MicroRNAs in chronic lymphocytic leukemia: An old disease with new genetic insights.

MicroRNA (2016) 5:106-112.

Harjes U et al.

Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.

Oncogene (2017) 36:912-921.

Miranda F et al.

Salt-inducible kinase 2 couples ovarian cancer cell metabolism with survival at the adipocyte-rich metastatic niche.

Cancer Cell (2016) 30:273-289.

Anfossi S & Calin GA.

Hodgkin lymphoma cells have a specific long noncoding RNA expression pattern.

Am J Pathol (2016) 186:2251-3.

Zhao Z et al.

An arginine finger regulates the sequential action of asymmetrical hexameric ATPase in the double-stranded DNA translocation motor.

Mol Cell Biol (2016) 36:2514-23.

Paladini L et al.

Targeting microRNAs as key modulators of tumor immune response.

J Exp Clin Cancer Res (2016) 35:103.

Higginbotham JN et al.

Identification and characterization of EGF receptor in individual exosomes by Fluorescence-Activated Vesicle Sorting.

J Extracell Vesicles (2016) 5:29254.

Srivastava A et al.

Exploitation of exosomes as nanocarriers for gene-, chemo-, and immune-therapy of cancer.

J Biomed Nanotechnol (2016) 12:1159-73.

Zhang HG et al.

Isolation, identification, and characterization of novel nanovesicles.

Oncotarget (2016) 7:41346-41362.

Chaluvally-Raghavan P et al.

Direct upregulation of STAT3 by microRNA-551b-3p deregulates growth and metastasis of ovarian cancer.

Cell Rep (2016) 15:1493-504.

Haemmerle M et al.

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

J Clin Invest (2016) 126:1885-96.

Ciccone M & Calin GA.

MicroRNAs in myeloid hematological malignancies.

Curr Genomics (2015) 16:336-48.

Yan KK et al.

Cross-disciplinary network comparison: Matchmaking between hairballs.

Cell Syst (2016) 2:147-157.

Wu SY et al.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Nat Commun (2016) 7:11169.

Van Roosbroeck K & Calin GA.

MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?

Semin Oncol (2016) 43:209-14.

Pan Y et al.

miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.

Oncotarget (2016) 7:25930-48.

Parasramka MA et al.

Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma.

Pharmacol Ther (2016) 161:67-78.

Huang J et al.

Dll4 inhibition plus aflibercept markedly reduces ovarian tumor growth.

Mol Cancer Ther (2016) 15:1344-52.

Almeida MI & Calin GA.

The miR-143/miR-145 cluster and the tumor microenvironment: Unexpected roles.

Genome Med (2016) 8:29.

Tanriverdi K et al.

Comparison of RNA isolation and associated methods for extracellular RNA detection by high-throughput quantitative Polymerase Chain Reaction.

Anal Biochem (2016) 501:66-74.

Rytelewski M et al.

Reciprocal positive selection for weakness – preventing olaparib resistance by inhibiting BRCA2.

Oncotarget (2016) 7:20825-39.

Zaborowski MP et al.

Extracellular vesicles: Composition, biological relevance, and methods of study.

Bioscience (2015) 65:783-797.

Zhang X et al.

Potential transfer of polyglutamine and CAG-repeat RNA in extracellular vesicles in Huntington”s disease: Background and evaluation in cell culture.

Cell Mol Neurobiol (2016) 36:459-70.

Olivieri M et al.

Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis.

Oncotarget (2016) 7:20636-54.

Kundu A et al.

Relation of atrial fibrillation in acute myocardial infarction to in-hospital complications and early hospital readmission.

Am J Cardiol (2016) 117:1213-8.

Rupaimoole R et al.

miRNA deregulation in cancer cells and the tumor microenvironment.

Cancer Discov (2016) 6:235-46.

Sun Y et al.

Examining plasma microRNA markers for colorectal cancer at different stages.

Oncotarget (2016) 7:11434-49.

Redis RS et al.

Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2.

Mol Cell (2016) 61:520-34.

Pua HH et al.

MicroRNAs 24 and 27 suppress allergic inflammation and target a network of regulators of T Helper 2 cell-associated cytokine production.

Immunity (2016) 44:821-32.

Hansen JM, Coleman RL & Sood AK.

Targeting the tumour microenvironment in ovarian cancer.

Eur J Cancer (2016) 56:131-43.

Guo P et al.

Biological nanomotors with a revolution, linear, or rotation motion mechanism.

Microbiol Mol Biol Rev (2016) 80:161-86.

Fabris L et al.

The potential of microRNAs as prostate cancer biomarkers.

Eur Urol (2016) 70:312-22.

Yuan T et al.

Plasma extracellular RNA profiles in healthy and cancer patients.

Sci Rep (2016) 6:19413.

Ben-Dov IZ et al.

Cell and microvesicle urine microRNA deep sequencing profiles from healthy individuals: Observations with potential impact on biomarker studies.

PLoS ONE (2016) 11:e0147249.

Mitamura T, Gourley C & Sood AK.

Prediction and failure of anti-angiogenesis escape.

Gynecol Oncol (2016) 141:80-5.

Lener T et al.

Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper.

J Extracell Vesicles (2015) 4:30087.

McManus DD et al.

Reliability of predicting early hospital readmission after discharge for an acute coronary syndrome using claims-based data.

Am J Cardiol (2016) 117:501-7.

Rupaimoole R et al.

Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis.

Cell Rep (2015) 13:2395-402.

Giza DE & Calin GA

microRNA and Chronic Lymphocytic Leukemia.

Adv Exp Med Biol (2015) 889:23-40.

Sercombe L et al.

Advances and challenges of liposome assisted drug delivery.

Front Pharmacol (2015) 6:286.

Silva A, Bullock M & Calin G.

The clinical relevance of long non-coding RNAs in cancer.

Cancers (2015) 7:2169-82.

Previs RA et al.

Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent antiangiogenic activity in ovarian cancer.

Mol Cancer Ther (2015) 14:2677-86.

Bucur O et al.

An updated h-index measures both the primary and total scientific output of a researcher.

Discoveries (2015) 3:3.

Wei S & Williams Z.

Rapid short-read sequencing and aneuploidy detection using MinION nanopore technology.

Genetics (2016) 202:37-44.

Pradeep S et al.

Erythropoietin stimulates tumor growth via EphB4.

Cancer Cell (2015) 28:610-22.

Schwarzenbach H et al.

Data normalization strategies for microRNA quantification.

Clin Chem (2015) 61:1333-42.

Monroig-Bosque Pdel C, Rivera CA & Calin GA.

MicroRNAs in cancer therapeutics: “From the bench to the bedside”.

Expert Opin Biol Ther (2015) 15:1381-5.

Chira S et al.

Progresses towards safe and efficient gene therapy vectors.

Oncotarget (2015) 6:30675-703.

Laurent LC et al.

Meeting report: Discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium.

J Extracell Vesicles (2015) 4:26533.

Giza DE, Vasilescu C & Calin GA.

Key principles of miRNA involvement in human diseases.

Discoveries (Craiova) (2014) 2:e34.

Ohtsuka M et al.

MicroRNA processing and human cancer.

J Clin Med (2015) 4:1651-67.

Ferrajoli A et al.

Epstein-Barr virus microRNAs are expressed in patients with chronic lymphocytic leukemia and correlate with overall survival.

EBioMedicine (2015) 2:572-82.

Nagaraja AS et al.

Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.

Oncogene (2016) 35:2390-7.

Matsuo K et al.

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Eur J Cancer (2015) 51:1978-88.

Reyes-Gonzalez JM et al.

Targeting c-MYC in platinum-resistant ovarian cancer.

Mol Cancer Ther (2015) 14:2260-9.

Ong WQ et al.

Heavy water: a simple solution to increasing the brightness of fluorescent proteins in super-resolution imaging.

Chem Commun (Camb) (2015) 51:13451-3.

Gharpure KM et al.

Nanotechnology: Future of oncotherapy.

Clin Cancer Res (2015) 21:3121-30.

Pichler M & Calin GA.

MicroRNAs in cancer: From developmental genes in worms to their clinical application in patients.

Br J Cancer (2015) 113:569-73.

Aslan B et al.

The ZNF304-integrin axis protects against anoikis in cancer.

Nat Commun (2015) 6:7351.

Pusic AD & Kraig RP.

Phasic treatment with Interferon gamma stimulates release of exosomes that protect against spreading depression.

J Interferon Cytokine Res (2015) 35:795-807.

Wang Q et al.

Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites.

Cancer Res (2015) 75:2520-9.

Miyake TM et al.

XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A.

Clin Cancer Res (2015) 21:3286-97.

Schwarzenbacher D et al.

Low spinophilin expression enhances aggressive biological behavior of breast cancer.

Oncotarget (2015) 6:11191-202.

Gilder AS et al.

Soluble Urokinase Receptor is released selectively by glioblastoma cells that express Epidermal Growth Factor Receptor variant III and promotes tumor cell migration and invasion.

J Biol Chem (2015) 290:14798-809.

Thanapprapa D Sr et al.

PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer.

Mol Cancer Ther (2015) 14:1466-1475.

Nouraee N, Mowla SJ & Calin GA.

Tracking miRNAs” footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy.

Genes Chromosomes Cancer (2015) 54:335-52.

Simonson B & Das S.

MicroRNA therapeutics: the next magic bullet?

Mini Rev Med Chem (2015) 15:467-74.

Ling H et al.

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.

Gut (2016) 65:977-989.

Ho GY et al.

Differential expression of circulating microRNAs according to severity of colorectal neoplasia.

Transl Res (2015) 166:225-32.

Ciccone M, Calin GA & Perrotti D.

From the biology of PP2A to the PADs for therapy of hematologic malignancies.

Front Oncol (2015) 5:21.

Kanada M et al.

Differential fates of biomolecules delivered to target cells via extracellular vesicles.

Proc Natl Acad Sci U S A (2015) 112:E1433-42.

Nick AM et al.

A framework for a personalized surgical approach to ovarian cancer.

Nat Rev Clin Oncol (2015) 12:239-45.

Martinez GJ et al.

The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells.

Immunity (2015) 42:265-78.

Ozcan G et al.

Preclinical and clinical development of siRNA-based therapeutics.

Adv Drug Deliv Rev (2015) 87:108-19.

Ling H et al.

Junk DNA and the long non-coding RNA Twist in cancer genetics.

Oncogene (2015) 34:5003-11.

Gonzalez-Villasana V et al.

Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer.

Clin Cancer Res (2015) 21:2127-37.

Haga H et al.

Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth.

J Extracell Vesicles (2015) 4:24900.

Choi HJ et al.

Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches.

Cancer Metastasis Rev (2015) 34:19-40.

Srivastava A et al.

Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment.

Curr Gene Ther (2015) 15:182-92.

Yao C et al.

Integromic analysis of genetic variation and gene expression identifies networks for cardiovascular disease phenotypes.

Circulation (2015) 131:536-49.

Berindan-Neagoe I & Calin GA.

Molecular pathways: microRNAs, cancer cells, and microenvironment.

Clin Cancer Res (2014) 20:6247-53.

Yang X et al.

New ways to successfully target tumor vasculature in ovarian cancer.

Curr Opin Obstet Gynecol (2015) 27:58-65.

Pusic AD et al.

Spreading depression transiently disrupts myelin via interferon-gamma signaling.

Exp Neurol (2015) 264:43-54.

Bottsford-Miller J et al.

Differential platelet levels affect response to taxane-based therapy in ovarian cancer.

Clin Cancer Res (2015) 21:602-10.

Melo SA et al.

Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.

Cancer Cell (2014) 26:707-21.

Danielson KM & Das S.

Extracellular vesicles in heart disease: Excitement for the future?

Exosomes Microvesicles (2014) 2:1.

Wen Y et al.

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.

Clin Cancer Res (2015) 21:448-59.

Previs RA et al.

Molecular pathways: Translational and therapeutic implications of the Notch signaling pathway in cancer.

Clin Cancer Res (2015) 21:955-61.

van den Beucken T et al.

Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.

Nat Commun (2014) 5:5203.

Rupaimoole R et al.

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

Nat Commun (2014) 5:5202.

Sato-Kuwabara Y et al.

The fusion of two worlds: Non-coding RNAs and extracellular vesicles–Diagnostic and therapeutic implications.

Int J Oncol (2015) 46:17-27.

Gyorgy B et al.

Therapeutic applications of extracellular vesicles: Clinical promise and open questions.

Annu Rev Pharmacol Toxicol (2015) 55:439-64.

Leung CS et al.

Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.

Nat Commun (2014) 5:5092.

Kutmon M et al.

WikiPathways app for Cytoscape: Making biological pathways amenable to network analysis and visualization.

F1000Research (2014) 3:152.

del C. Monroig P et al.

Small molecule compounds targeting miRNAs for cancer therapy.

Adv Drug Deliv Rev (2015) 81:104-16.

Braicu C et al.

Exosomes as divine messengers: Are they the Hermes of modern molecular oncology?

Cell Death Differ (2015) 22:34-45.

Gonzalez-Villasana V et al.

Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.

Mol Cancer Ther (2014) 13:2583-94.

Mata IF et al.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

JAMA Neurol (2014) 71:1405-12.

Han C et al.

The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression.

Cell Rep (2014) 8:1447-60.

Berindan-Neagoe I et al.

MicroRNAome genome: a treasure for cancer diagnosis and therapy.

CA Cancer J Clin (2014) 64:311-36.

Ren A & Patel DJ.

c-di-AMP binds the ydaO riboswitch in two pseudo-symmetry-related pockets.

Nat Chem Biol (2014) 10:780-6.

Krzeszinski JY et al.

MiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.

Nature (2014) 512:431-5.

Pradeep S et al.

Hematogenous metastasis of ovarian cancer: Rethinking mode of spread.

Cancer Cell (2014) 26:77-91.

Davis AN, Afshar-Kharghan V & Sood AK.

Platelet effects on ovarian cancer.

Semin Oncol (2014) 41:378-84.

Takahashi K et al.

Analysis of extracellular RNA by digital PCR.

Front Oncol (2014) 4:129.

Wu SY et al.

RNAi therapies: Drugging the undruggable.

Sci Transl Med (2014) 6:240ps7.

Yang L et al.

Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.

Mol Syst Biol (2014) 10:728.

Freedman JE.

Inherited dysfunctional nitric oxide signaling and the pathobiology of atherothrombotic disease.

Circ Res (2014) 114:1372-3.

Gharpure KM et al.

Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer.

Mol Cancer Ther (2014) 13:1750-7.

Tucker SL et al.

Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

Clin Cancer Res (2014) 20:3280-8.

Hochberg FH et al.

Glioma diagnostics and biomarkers: An ongoing challenge in the field of medicine and science.

Expert Rev Mol Diagn (2014) 14:439-52.

Hu W et al.

Notch3 pathway alterations in ovarian cancer.

Cancer Res (2014) 74:3282-93.

Lindoso RS et al.

Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury.

Stem Cells Dev (2014) 23:1809-19.

Wu SY et al.

2”-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Nat Commun (2014) 5:3459.

Cho MS et al.

Autocrine effects of tumor-derived complement.

Cell Rep (2014) 6:1085-95.

Quesenberry PJ et al.

Cellular phenotype and extracellular vesicles: Basic and clinical considerations.

Stem Cells Dev (2014) 23:1429-36.

Dalton HJ et al.

Monocyte subpopulations in angiogenesis.

Cancer Res (2014) 74:1287-93.

Zhaorigetu S et al.

Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue.

J Liposome Res (2014) 24:182-90.

McManus DD et al.

Relations between circulating microRNAs and atrial fibrillation: Data from the Framingham Offspring Study.

Heart Rhythm (2014) 11:663-9.

Ozpolat B, Sood AK & Lopez-Berestein G.

Liposomal siRNA nanocarriers for cancer therapy.

Adv Drug Deliv Rev (2014) 66:110-6.

Panagopoulos K et al.

Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure.

Mol Cancer (2013) 12:118.

Aslan B et al.

Nanotechnology in cancer therapy.

J Drug Target (2013) 21:904-13.

Pecot CV et al.

Tumour angiogenesis regulation by the miR-200 family.

Nat Commun (2013) 4:2427.

Nishimura M et al.

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Cancer Discov (2013) 3:1302-15.